Results 91 to 100 of about 3,057 (155)

Enfortumab Vedotin Following Platinum Chemotherapy and Avelumab Maintenance in Patients with Metastatic Urothelial Carcinoma: A Retrospective Data from the ARON-2EV Study [PDF]

Catalano, Martina, Roviello, Giandomenico   +1 more
core   +1 more source

Immune checkpoint inhibitors in urothelial bladder cancer: State of the art and future perspectives [PDF]

, 2021
Nesi, G., Palmieri, V. E., Roviello, G., Santi, R., Villari, D.   +4 more
core   +1 more source

Cavitation of Pulmonary Metastases During Enfortumab Vedotin for Metastatic Ureteral Urothelial Carcinoma. [PDF]

IJU Case Rep
Ito F, Kobayashi K, Hayashi G, Kamijo S, Fujita T.   +4 more
europepmc   +1 more source

Enfortumab vedotin-related hemorrhagic vesicular eruption managed with dose reduction. [PDF]

JAAD Case Rep
Mueller K, Pei S, Bogner P, Kuraitis D.
europepmc   +1 more source

Real-world use of enfortumab vedotin in metastatic urothelial carcinoma: efficacy, safety, and risk stratification. [PDF]

Ther Adv Urol
Catalano M, Bartoli S, Salfi A, Bonalda M, Della Seta L, Paulet A, Bloise F, Paolieri F, Galli L, Sisani M, Doni L, Perrella A, Antonuzzo L, Roviello G.   +13 more
europepmc   +1 more source

Real-world effectiveness of avelumab, pembrolizumab, and enfortumab vedotin in patients with advanced urothelial carcinoma with squamous differentiation (ARON-2EV). [PDF]

Cancer Immunol Immunother
Mollica V, Massari F, Fujita K, Giannatempo P, Grande E, Büttner T, Bourlon MT, Taha T, Fukuokaya W, Myint ZW, Pichler R, Binz K, Molina-Cerrillo J, Kopecky J, de Liaño AG, Kucharz J, Fiala O, Matrana MR, Kopp RM, Di Civita MA, Zgura A, Ansari J, Kihnel R, De Felice F, Angel M, Monteiro FSM, Soares A, Urun Y, Buti S, Santini D, Santoni M.   +30 more
europepmc   +1 more source

Advanced urothelial carcinoma treated with enfortumab vedotin and pembrolizumab: a path to cure? [PDF]

Oncologist
Jang A, Tripathi N, Lanka SM, Kumar HLS, Jain P, Calaway A, Shoag JE, Vince R, Mendiratta P, Rao S, Garcia JA, Brown JR, Koshkin VS, Campbell MT, Singh P, Barata PC.   +15 more
europepmc   +1 more source

Are primary tumors suitable for biomarker-guided treatment of metastatic urothelial cancer? [PDF]

Boormans, Joost L., Robbrecht, Debbie G.J., Scholtes, Mathijs P., van Leenders, Geert J.L.H., Zuiverloon, Tahlita C.M.   +4 more
core   +2 more sources

Nectin-4 PET for predicting enfortumab vedotin dose-response in urothelial carcinoma. [PDF]

Sci Adv
Mishra A, Sharma AK, Gupta K, Banka DS, Johnson BA, Hoffman-Censits J, Huang P, McConkey DJ, Nimmagadda S.   +8 more
europepmc   +1 more source

Case Report: Zinc deficiency as a modifiable risk factor for enfortumab vedotin-induced cutaneous adverse events. [PDF]

Front Oncol
Nishizawa A, Itoh M, Inoue M, Makiguchi M, Koga F.   +4 more
europepmc   +1 more source